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Sirs: A 28-year-old Guinese man
was admitted to our hospital with a
3-week history of severe headache,
vomiting and fever. Ten months
earlier he was diagnosed with
AIDS. The presenting AIDS-deﬁn-
ing illness then, was disseminated
cryptococcosis: Cryptococcus neo-
formans had been recovered from
CSF, bronchoalveolar washings,
and blood. Standard treatment of
CM with amphotericin B and ﬂu-
cytosine followed by ﬂuconazole
[1] resulted in clinical and micro-
biological cure. The patient had
been taking ﬂuconazole 200 mg
QD PO as secondary prophylaxis
since. After successful treatment of
CM, HAART was initiated. This
preceded admission by 320 days.
The CD4 cell count rose from 0 to
120 cells/ll and HIV1-RNA to
undetectable levels (<50 copies/
ml). There was no reason to doubt
compliance to ﬂuconazole pro-
phylaxis.
On examination an ill-looking
man was seen, with low-grade
pyrexia and stable haemodynam-
ics. He was alert and cooperative,
with no signs of meningism or
mental confusion. Neurological
examination and further physical
examination revealed no abnor-
malities. Laboratory results were
unremarkable. Brain CT-scan
without contrast did not show any
mass lesions, or hydrocephalus.
Clear CSF was obtained, opening
pressure was >50 cm H2O. CSF
contained 0.59 g/l protein,
3.0 mmol/l glucose (at a serum
glucose concentration of
5.1 mmol/l) and 272 · 10
6/l leu-
kocytes, mainly monocytic. It
tested positive for cryptococcal
antigen. Considering relapse CM,
treatment appropriate to this
diagnosis was initiated (ampho-
tericin B 1 mg/kg intravenously
per day and ﬂucytosine 100 mg/
kg/d PO).
After 1 week his headache and
malaise had not improved. Both
stain and culture were negative for
Cryptococcus neoformans. Crypto-
coccal antigen titers were found to
be low: 1:16 in serum and 1:4 in
CSF. Therefore the diagnosis was
revised to Cryptococcus neofor-
mans-related immune reconstitu-
tion inﬂammatory syndrome
(IRIS).
Antifungal treatment was dis-
continued and prednisone was
prescribed (1 mg/kg/day IV).
One more lumbar puncture was
needed for temporary relief of
symptoms due to raised CSF
pressure. Our patient made a
dramatic recovery and was dis-
charged from hospital 3 days later,
symptom-free. Prednisone was ta-
pered in 4 months.
IRIS can manifest itself as a
latent infection unmasked by im-
mune reconstitution, or as sterile
inﬂammation in response to per-
sisting antigens of an infection
already treated. Therefore, latent
infection should be ruled out in
patients commencing antiretrovi-
ral therapy.
Key to the diagnosis of crypto-
coccal-related IRIS in patients
treated with HAART is the ab-
sence of fungal cells in all cultures.
Cryptococcal antigen in blood or
CSF of HIV-infected patients pre-
viously treated for CM, is a poor
marker of infection [2]. Shelburne
et al. found low cryptococcal
antigen titres of value in discrim-
inating cryptococcal-related IRIS
from CM in a retrospective cohort
study [3]. Other factors predictive
of cryptococcal-related IRIS are a
higher white blood cell count in
CSF, higher CSF glucose and a
higher CD4 cell count. . Lumbar
puncture opening pressure was
signiﬁcantly higher in the IRIS
group. These ﬁndings reﬂect the
inﬂammatory nature of the syn-
drome due to immune restoration.
The presence of the following risk
factors for IRIS support the diag-
nosis in this case: a rise in CD4 cell
count, a decrease in viral load, and
compliance with a secondary pro-
phylactic treatment regime of
ﬂuconazole.
For treatment of the aseptic
meningitis, anti-inﬂammatory
drugs are a logical choice. Short-
term corticosteroid administration
was shown to be safe and well
tolerated in patients who are
receiving antiretroviral treatment
[4]. It proved beneﬁcial to prevent
paradoxical reactions in tubercu-
lous meningitis [5] and in other
described cases of cryptococcal
meningitis associated IRIS [6]. At
a dose of 60 mg prednisone IV,
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ever, studies deﬁning the role of
corticosteroids in IRIS are ur-
gently needed. The use of corti-
costeroids was demonstrated to be
harmful in CM or cryptococcoma
[7]. Therefore, exclusion of active
cryptococcal disease remains the
most important step in managing
Cryptococcus neoformans—related
IRIS.
Guidelines for the treatment of
CM recommend daily lumbar
punctures in all patients with ini-
tially elevated opening pressures
(>25 cm H2O) until the pressure is
adequately controlled [1, 7]. Since
the mechanism for increased
intracranial pressure is thought to
be the same in CM and crypto-
coccal IRIS, adherence to these
guidelines seems prudent.
Concluding, the HIV-positive
patient treated with highly active
antiretroviral therapy and return-
ing meningeal symptoms after
treatment for cryptococcal men-
ingitis is diagnostically challeng-
ing. Distinguishing between
Cryptococcus neoformans—related
IRIS and active cryptococcal dis-
ease as two different clinical enti-
ties is crucial.
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